Soliqua 100/33 contains two active ingredients, insulin glargine and lixisenatide. (An active ingredient is what makes a medication work.) Each active ingredient has its own mechanism of action ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

When a GLP-1 drug similar to Ozempic helped slow Parkinson's symptoms A recent New England Journal of Medicine study tested lixisenatide, a GLP-1 drug, as a potential treatment for early-stage ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...